Income Statement
ABCELLERA BIOLOGICS INC.
ABCL
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
75.13 | 28.83 | 38.03 | 485.42 | 375.20 |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
75.13 | 28.83 | 38.03 | 485.42 | 375.20 |
|
Operating Expenses
|
292.23 | 343.60 | 275.23 | 268.91 | 170.79 |
|
Research & Development
|
186.83 | 167.26 | 175.66 | 107.88 | 62.06 |
|
Selling, General & Administrative
|
83.23 | 72.71 | 61.00 | 55.49 | 41.85 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-217.10 | -314.77 | -237.21 | 216.51 | 204.41 |
|
Non-Operating Income
|
39.51 | 114.37 | 63.18 | 22.59 | 14.74 |
|
Interest Income
|
28.33 | 38.47 | 42.25 | 16.08 | 3.33 |
|
Interest Expense
|
- | - | - | - | - |
|
Other Non-Op Income / Expense
|
1.80 | 1.70 | 1.80 | -4.05 | -5.23 |
|
Income Before Tax
|
-177.60 | -200.40 | -174.03 | 239.10 | 219.15 |
|
Income Tax Expense
|
-31.18 | -37.54 | -27.63 | 80.58 | 65.69 |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-146.41 | -162.86 | -146.40 | 158.52 | 153.46 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-217.10 | -314.77 | -212.81 | 216.51 | 218.86 |
|
Earnings Per Share (Basic)
|
-0.49 | -0.55 | -0.51 | 0.56 | 0.56 |
|
Diluted EPS
|
-0.49 | -0.55 | -0.51 | 0.50 | 0.48 |
|
Weighted Average Shares
|
298.71 | 294.33 | 289.17 | 285.06 | 275.76 |
|
Diluted Weighted Avg Shares
|
298.71 | 294.33 | 289.17 | 314.83 | 318.29 |
|
Comprehensive Income
|
-146.27 | -165.52 | -146.73 | 156.85 | 153.74 |